Immunome, Inc. (IMNM) Stock

Immunome, Inc. (IMNM) is a Healthcare stock trading at $18.73 (as of 2026-06-18), with a market capitalization of $2.47B and a trailing P/E of -7.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Immunome, Inc. is a biopharmaceutical company that discovers and develops antibody therapeutics for oncology and infectious disease. Its pipeline includes IMM-ONC-01, targeting IL-38, and IMM-BCP-01, an antibody cocktail candidate for SARS-CoV-2 infection and COVID-19.

Valuation — source: SEC EDGAR (first-party)
Price	$18.73
Market Cap	$2.47B
P/E Ratio	-7.7
EV / EBITDA	-6.3
Price / Book	3.54
Price / Sales	518.44
DCF Value (model)	$-24.41
DCF Upside vs Price	-230.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$6.94M
Net Margin	-3060.0%
Return on Equity	-38.2%
Current Ratio	21.68
Revenue Growth (YoY)	-23.2%
EPS Growth (YoY)	-51.4%
FCF Growth (YoY)	70.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	24.55 (safe)

Valuation vs Sector & Industry
Stock P/E	-7.7
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-136.7%
vs Industry	-144.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FMR LLC ($371.13M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Clay Siegall
Employees	131
Country	US
IPO Date	2020-10-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.